---
title: "RedHill Biopharma Ltd. (RDHL.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/RDHL.US.md"
symbol: "RDHL.US"
name: "RedHill Biopharma Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T12:31:16.025Z"
locales:
  - [en](https://longbridge.com/en/quote/RDHL.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/RDHL.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/RDHL.US.md)
---

# RedHill Biopharma Ltd. (RDHL.US)

## Company Overview

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers’ diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn’s disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.redhillbio.com](https://www.redhillbio.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:15.000Z

**Overall: C (0.54)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 105 / 189 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% |  |
| Net Profit YoY | 94.81% |  |
| P/B Ratio | 1.11 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 4745268.57 |  |
| Revenue | 286000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 3893.98% | A |
| Profit Margin | -150.00% | E |
| Gross Margin | 100.00% | A |
| Revenue YoY | 0.00% | D |
| Net Profit YoY | 94.81% | A |
| Total Assets YoY | 40.47% | A |
| Net Assets YoY | 191.14% | A |
| Cash Flow Margin | 1676.22% | A |
| OCF YoY | 0.00% | D |
| Turnover | 0.01 | E |
| Gearing Ratio | 83.16% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - RedHill Biopharma Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "94.81%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.11",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "4745268.57",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "286000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "3893.98%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-150.00%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "94.81%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "40.47%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "191.14%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "1676.22%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.01",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "83.16%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -11.06 | 192/189 | - | - | - |
| PB | 1.11 | 55/189 | 1.25 | 1.22 | 1.21 |
| PS (TTM) | 16.59 | 128/189 | 0.62 | 0.51 | 0.40 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2023-02-17T05:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.93 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/RDHL.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/RDHL.US/norm.md)
- [Related News](https://longbridge.com/en/quote/RDHL.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/RDHL.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**